Sorafenib

Form: Film Coated Tablet

Strength: 200 mg

Reference Brands: Nexavar (EU & US)

Category: Oncology Cancer Care

Sorafenib Tablets 200 mg are a key oncology treatment used in the management of advanced cancers such as hepatocellular carcinoma (HCC), renal cell carcinoma (RCC), and differentiated thyroid carcinoma refractory to radioactive iodine. As a multikinase inhibitor, Sorafenib targets tumor cell proliferation and angiogenesis, making it effective in slowing cancer progression. Approved in both the U.S. and EU under the brand name Nexavar, with multiple generic versions available, Sorafenib is a vital product for pharmaceutical B2B distribution. Available in 200 mg film-coated tablets, it meets global oncology standards and supports hospitals and cancer centers in advanced cancer care.